These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 29618499)

  • 41. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
    Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
    J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.
    Winters MA; Lloyd RM; Shafer RW; Kozal MJ; Miller MD; Holodniy M
    PLoS One; 2012; 7(7):e40514. PubMed ID: 22815755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.
    Moscona R; Ram D; Wax M; Bucris E; Levy I; Mendelson E; Mor O
    J Int AIDS Soc; 2017 Aug; 20(1):21846. PubMed ID: 28799325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.
    Vandenhende MA; Bellecave P; Recordon-Pinson P; Reigadas S; Bidet Y; Bruyand M; Bonnet F; Lazaro E; Neau D; Fleury H; Dabis F; Morlat P; Masquelier B
    PLoS One; 2014; 9(1):e86771. PubMed ID: 24475178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a new comprehensive HIV-1 genotypic drug resistance assay for all commercially available reverse transcriptase, protease and integrase inhibitors in patients infected with group M HIV-1 strains.
    Chrysostomou AC; Topcu C; Stylianou DC; Hezka J; Kostrikis LG
    Infect Genet Evol; 2020 Jul; 81():104243. PubMed ID: 32061896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene.
    Nicot F; Jeanne N; Raymond S; Delfour O; Carcenac R; Lefebvre C; Sauné K; Delobel P; Izopet J
    J Med Virol; 2018 Sep; 90(9):1486-1492. PubMed ID: 29750364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors.
    Peduzzi C; Pierotti P; Venturi G; Romano L; Mazzotta F; Zazzi M
    J Clin Virol; 2002 Jul; 25(1):57-62. PubMed ID: 12126722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
    Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden.
    Andersson E; Ambikan A; Brännström J; Aralaguppe SG; Yilmaz A; Albert J; Neogi U; Sönnerborg A
    AIDS; 2021 Feb; 35(2):227-234. PubMed ID: 33394670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Technologies for HIV-1 drug resistance testing: inventory and needs.
    Metzner KJ
    Curr Opin HIV AIDS; 2022 Jul; 17(4):222-228. PubMed ID: 35762377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing.
    López-Aladid R; Guiu A; Mosquera MM; López-Medrano F; Cofán F; Linares L; Torre-Cisneros J; Vidal E; Moreno A; Aguado JM; Cordero E; Martin-Gandul C; Carratalá J; Sabé N; Niubó J; Cervera C; Capón A; Cervilla A; Santos M; Bodro M; Muñoz P; Fariñas MC; Antón A; Aranzamendi M; Montejo M; Pérez-Romero P; Len O; Marcos MÁ
    PLoS One; 2019; 14(7):e0219701. PubMed ID: 31318908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children.
    Gopalan BP; D'Souza RR; Rajnala N; Arumugam K; Dias M; Ranga U; Shet A
    J Med Virol; 2019 Jun; 91(6):1036-1047. PubMed ID: 30695102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic landscape for majority and minority HIV-1 drug resistance mutations in antiretroviral therapy naive patients in Accra, Ghana.
    Appiah P; Gbassana G; Adusei-Poku M; Obeng BM; Duedu KO; Sagoe KWC
    Heliyon; 2024 Jun; 10(12):e33180. PubMed ID: 39022058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 Genotypic Resistance Testing Using Sanger and Next-Generation Sequencing in Adults with Low-Level Viremia in China.
    Li Q; Yu F; Song C; Zhao H; Xiao Q; Lao X; Yang S; Tang Y; Zhang F
    Infect Drug Resist; 2022; 15():6711-6722. PubMed ID: 36438645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.
    Chaillon A; Nakazawa M; Wertheim JO; Little SJ; Smith DM; Mehta SR; Gianella S
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing.
    Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Abdurahman S; Marrone G; Neogi U; Tegbaru B; Sönnerborg A
    Sci Rep; 2018 May; 8(1):7556. PubMed ID: 29765082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amino Acid Prevalence of HIV-1
    Tzou PL; Rhee SY; Shafer RW
    AIDS Res Hum Retroviruses; 2019 Oct; 35(10):924-929. PubMed ID: 31317771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.